UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

  (Check One):  

[X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ]  Form 10-D [  ] Form N-SAR [  ] Form N-CSR

       
      For Period Ended: December 31, 2018
       
      [  ]   Transition Report on Form 10-K
      [  ]   Transition Report on Form 20-F
      [  ]   Transition Report on Form 11-K
      [  ]   Transition Report on Form 10-Q
      [  ]   Transition Report on Form N-SAR
       
      For the Transition Period Ended:                               

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

 

Adhera Therapeutics, Inc.

Full Name of Registrant
 
N/A

Former Name if Applicable

 

4721 Emperor Boulevard, Suite 350

Address of Principal Executive Office (Street and Number)

 

Durham, North Carolina 27703

City, State and Zip Code

 

 

 

 
 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

[X]   (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[X]   (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
[  ]    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Adhera Therapeutics, Inc. (the “Registrant”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “Form 10-K”). The compilation, dissemination and review of the information required to be presented in the Form 10-K for the relevant period, including, without limitation, the financial statements to be included therein, following the recent resignation of the Chief Financial Officer of the Registrant, has imposed time constraints that have rendered timely filing of the Form 10-K impracticable without undue hardship and expense to the Registrant. The Registrant undertakes the responsibility to file, and anticipates that it will file, the Form 10-K no later than fifteen days after its original prescribed due date.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Uli Hacksell, Ph.D., Chairman

   (919)   578-5901
(Name)   

(Area Code)

  (Telephone Number)

  

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
  [X] Yes [  ] No
   

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
  [  ] Yes [X] No
   
   
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
 

 

Adhera Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 2, 2019 By: /s/ Uli Hacksell, Ph.D.
 

Uli Hacksell, Ph.D.

Chairman

 

 
 

Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).
Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).